Status:
RECRUITING
Naringenin Supplementation in Bone Fracture Patients
Lead Sponsor:
Shahid Beheshti University of Medical Sciences
Conditions:
Bone Fractures
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
Fractures of the lower extremities represent a significant proportion of injuries sustained by polytrauma patients, with a notable association with prolonged hospitalization, chronic disability, and i...
Detailed Description
The study subjects will be selected from among the patients with bone fractures of the lower limbs who are hospitalized in the orthopedic department of Ayatollah Taleghani University Hospital in Tehra...
Eligibility Criteria
Inclusion
- Candidate for orthopedic surgery for bone fractures of the lower limbs,
- Ambulatory without assistance for a minimum of two months prior to the fracture.
- Not having undergone amputation of the lower limbs.
- Not suffering from liver cirrhosis.
- Not suffering from advanced kidney failure (blood creatinine higher than 1.4 mg/dL).
- Not having metastatic cancer, any chronic inflammatory diseases, nor taking any drugs that affect bone metabolism, including calcitonin, bisphosphonates, and corticosteroids.
Exclusion
- Allergy or intolerant reaction to narangenin capsules
- Any abnormal changes in their liver, kidneys tests,
- Failure to consume more than 10% of their capsules
Key Trial Info
Start Date :
November 3 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 12 2026
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT06612762
Start Date
November 3 2024
End Date
March 12 2026
Last Update
November 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ayatollah Taleghani Educational Hospital
Tehran, Iran